Skip to main content
Figure 5 | Molecular Cancer

Figure 5

From: Preclinical analysis of the anti-tumor and anti-metastatic effects of Raf265 on colon cancer cells and CD26+ cancer stem cells in colorectal carcinoma

Figure 5

Activated Raf/MEK/ERK signaling pathway of CD26+ cells. CD26+ and CD26 cells sorted from tumor samples, HT29 and HCT116 cells were lysed and subjected to western blot analysis. Representing blots of the expression of total Braf, MEK and ERK, and the phosphorylation of MEK and ERK were shown. The expression level of β-actin was used as the loading control. At the lower panel, a bar chart presenting the ratio of Braf vs. β-actin, p.MEK vs. TL. MEK and p.ERK vs TL. ERK was shown. Data are presented as means ± SD from three independent experiments and statistical analysis was performed by one-way ANOVA. *p < 0.05 versus CD26 cells of the corresponding samples.

Back to article page